Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | PI4KA | P42356 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28397163 | 0.89 | APP (0.51) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL29837272 | 0.87 | KDM4E (0.50) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23634035 | 0.87 | KDM4E (0.50) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL29837257 | 0.85 | KDM4E (0.48) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL29837259 | 0.85 | KDM4E (0.48) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL30461568 | 0.84 | KDM4E (0.49) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL16943516 | 0.84 | KDM4E (0.49) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23634034 | 0.83 | KDM4E (0.47) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL13863152 | 0.83 | APP (0.47) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23634037 | 0.82 | KDM4E (0.46) | KDM4EMEN1KMT2APOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030838-B1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | PFIZER PROD INC (US) | 2003-01-22 | — | — | EP | claimed |
| US-6262272-B1 | REACTING FURAN CARBOXYLIC ACID DERIVATIVE WITH ACID CHLORIDE OR ACID ANHYDRIDE IN INERT SOLVENT CONTAINING ACID RECEPTOR; ADDING AROMATIC AMINE COMPOUND TO FORM PYRROLE CARBOXAMIDE COMPOUND | PFIZER INC | 2001-07-17 | — | — | US | claimed |
| EP-1030838-A1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | Pfizer Products Inc. (US) | 2000-08-30 | — | — | EP | claimed |
| WO-1999025684-A1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | PFIZER PRODUCTS INC. (US) | 1999-05-27 | — | — | WO | claimed |
| CN-113710664-B | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| CN-110291455-B | Liquid crystal aligning agent, liquid crystal alignment film and method for producing the same, liquid crystal element and polymer | JSR株式会社 | 2022-03-22 | — | — | CN | disclosed |
| US-11197867-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210377495-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2021-12-02 | — | — | US | disclosed |
| CN-108047142-B | Heteroaryl compounds and uses thereof | 西建卡尔有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-1030838-B1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | PFIZER PROD INC (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6262272-B1 | REACTING FURAN CARBOXYLIC ACID DERIVATIVE WITH ACID CHLORIDE OR ACID ANHYDRIDE IN INERT SOLVENT CONTAINING ACID RECEPTOR; ADDING AROMATIC AMINE COMPOUND TO FORM PYRROLE CARBOXAMIDE COMPOUND | PFIZER INC | 2001-07-17 | — | — | US | disclosed |
| EP-1030838-A1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | Pfizer Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999025684-A1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | PFIZER PRODUCTS INC. (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | JAK1, JAK2, JAK3 | PIK3CD 155/4885PIK3CA 198/4885PIK3CB 217/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | PIK3CD 941/4885PIK3CA 1559/4885PIK3CB 765/4885 |
| US-11197867-B2 | Aminopyrimidinyl compounds | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 | PIK3CD 3242/4885PIK3CA 3238/4885PIK3CB 2949/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PIK3CD 58/4885PIK3CA 17/4885PIK3CB 41/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | PIK3CD 1738/4885PIK3CA 524/4885PIK3CB 1711/4885 |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PIK3CD 3017/4885PIK3CA 2051/4885PIK3CB 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.